AR133249A1 - Nuevos compuestos - Google Patents
Nuevos compuestosInfo
- Publication number
- AR133249A1 AR133249A1 ARP240101825A ARP240101825A AR133249A1 AR 133249 A1 AR133249 A1 AR 133249A1 AR P240101825 A ARP240101825 A AR P240101825A AR P240101825 A ARP240101825 A AR P240101825A AR 133249 A1 AR133249 A1 AR 133249A1
- Authority
- AR
- Argentina
- Prior art keywords
- prevention
- treatment
- present
- diseases
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a nuevos compuestos, a dichos compuestos para su uso como un medicamento, más específicamente para la prevención o tratamiento de enfermedades mediadas por la actividad de PTPN2 y/o PTPN1, aún más específicamente para la prevención o tratamiento del cáncer o enfermedades metabólicas. La presente invención además se refiere a un método para la prevención o tratamiento de dichas enfermedades que comprende el uso de los nuevos compuestos. La presente invención además se refiere a composiciones farmacéuticas o preparaciones combinadas de los nuevos compuestos, así como a dichas composiciones o preparaciones para su uso como un medicamento, con mayor preferencia para la prevención o tratamiento de enfermedades mediadas por la actividad de PTPN2 y/o PTPN1, aún más específicamente para la prevención o tratamiento del cáncer o enfermedades metabólicas. La presente invención además se refiere a procesos para la preparación de dichos compuestos. Un compuesto de la fórmula (1), una forma estereoisomérica, un tautómero, una sal (en particular una sal farmacéuticamente aceptable), un solvato, un hidrato, un polimorfo, un isótopo, y/o un profármaco del mismo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP23185489 | 2023-07-14 | ||
| EP24182972 | 2024-06-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR133249A1 true AR133249A1 (es) | 2025-09-10 |
Family
ID=91856247
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP240101825A AR133249A1 (es) | 2023-07-14 | 2024-07-12 | Nuevos compuestos |
| ARP240101826A AR133250A1 (es) | 2023-07-14 | 2024-07-12 | Nuevos compuestos |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP240101826A AR133250A1 (es) | 2023-07-14 | 2024-07-12 | Nuevos compuestos |
Country Status (3)
| Country | Link |
|---|---|
| AR (2) | AR133249A1 (es) |
| TW (2) | TW202519514A (es) |
| WO (2) | WO2025016906A1 (es) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| KR20080074966A (ko) * | 2005-12-08 | 2008-08-13 | 노파르티스 아게 | 1,1,3-트리옥소-1,2,5-티아디아졸리딘 및 ｐｔｐ-ａｓｅ억제제로서의 그의 용도 |
| UA94921C2 (en) * | 2005-12-08 | 2011-06-25 | Новартис Аг | 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors |
| CA3131894A1 (en) | 2019-03-14 | 2020-09-17 | Calico Life Sciences Llc | Protein tyrosine phosphatase inhibitors and methods of use thereof |
| CN116348455A (zh) | 2019-12-18 | 2023-06-27 | 卡里科生命科学有限责任公司 | 蛋白质酪氨酸磷酸酶抑制剂和其使用方法 |
| JP2023508914A (ja) | 2019-12-20 | 2023-03-06 | カリコ ライフ サイエンシーズ エルエルシー | プロテインチロシンホスファターゼ分解剤及びその使用方法 |
| AU2022234402A1 (en) | 2021-03-11 | 2023-09-28 | Kumquat Biosciences Inc. | Heterocycles and uses thereof |
| EP4436967A4 (en) | 2021-11-23 | 2025-10-22 | Kumquat Biosciences Inc | COMPOUNDS CONTAINING HETEROATOMS AND THEIR USES |
| CN117658947A (zh) * | 2022-09-06 | 2024-03-08 | 杭州中美华东制药有限公司 | 蛋白酪氨酸磷酸酶抑制作用的5-(取代芳基)-1,2,5-噻二唑啉-3-酮类化合物 |
-
2024
- 2024-07-12 TW TW113126297A patent/TW202519514A/zh unknown
- 2024-07-12 WO PCT/EP2024/069828 patent/WO2025016906A1/en active Pending
- 2024-07-12 AR ARP240101825A patent/AR133249A1/es unknown
- 2024-07-12 TW TW113126300A patent/TW202519209A/zh unknown
- 2024-07-12 AR ARP240101826A patent/AR133250A1/es unknown
- 2024-07-12 WO PCT/EP2024/069833 patent/WO2025016909A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2025016909A1 (en) | 2025-01-23 |
| WO2025016906A1 (en) | 2025-01-23 |
| TW202519514A (zh) | 2025-05-16 |
| TW202519209A (zh) | 2025-05-16 |
| AR133250A1 (es) | 2025-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022010460A2 (es) | Compuestos tricíclicos sustituidos | |
| CR20230616A (es) | Análogos de triazolo pirimidina para el tratamiento de enfermedades relacionadas con la inhibición de la helicasa recq del síndrome de werner (wrn) | |
| CL2022000271A1 (es) | Inhibidores de la fosfatasa shp2 de pirazolo(3,4-b)pirazina. | |
| BR112022003514A2 (pt) | Degradadores bifuncionais de brd9 e seus métodos de uso | |
| CO2022008997A2 (es) | Compuestos tricíclicos sustituidos | |
| CL2023000921A1 (es) | Derivados de 1,2,3,4-tetrahidroquinolina como inhibidores de la activacion de yap/taz-tead | |
| UA109698C2 (xx) | Похідні азаіндазолу або діазаіндазолу як медикамент | |
| MX2021011606A (es) | Compuestos dirigidos a prmt5. | |
| BRPI0607926A2 (pt) | compostos espiro-oxindol e seus usos como agentes terapêuticos | |
| CL2023003223A1 (es) | Derivado de fosfonilo, y composición y aplicación farmacéutica de este | |
| PE20181778A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicacion viral del dengue | |
| MX2022003617A (es) | Derivados heterociclicos, composiciones farmaceuticas y su uso en el tratamiento o mejora del cancer. | |
| UY39799A (es) | Compuestos de pirrolil–sulfonamida | |
| MX2024002409A (es) | Terapias contra el cancer. | |
| CO2024015371A2 (es) | Derivados de oxoindolinil amida para inhibir nlrp3 y usos de los mismos | |
| AR128622A1 (es) | Inhibidores de la cinasa mek | |
| MX2022006333A (es) | Compuesto triheterociclico como inhibidor de jak y uso del mismo. | |
| CO2022008616A2 (es) | Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma | |
| CR20250124A (es) | Compuestos para el tratamiento del cáncer | |
| CL2019003467A1 (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias. | |
| AR133249A1 (es) | Nuevos compuestos | |
| MX2022016497A (es) | Derivados heterociclicos, composiciones farmaceuticas y su uso en el tratamiento, mejora o prevencion de la enfermedad fibrotica. | |
| AR128100A1 (es) | Compuestos para el tratamiento de la pérdida del cabello | |
| CO2022004768A2 (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
| UY39466A (es) | Compuestos y composiciones para el tratamiento de la criptosporidiosis |